InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has appointed Gerard (Jerry) P. Griffin III as vice president of sales and marketing at BayMedica, a wholly owned subsidiary of InMed. In his new role, Griffin will manage the commercialization of BayMedica’s health and wellness business including existing products as well as the launch of new products. Griffin brings a rich background to this position, having a proven track record as a veteran sales executive. He has served in several senior positions in Fortune 500 companies, including most recently as VP of sales and business development at Creo Ingredients, a biotechnology-based ingredient company that produces rare cannabinoids. Before that, he was president of a successful wellness company. In addition, InMed released its Q2 2022 financial and corporate update. Highlights of that report include the company’s acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sector, as well its strengthened IP, resulting from patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseases. In addition, the company saw the commercial rollout CBT, the first of several rare cannabinoid launches planned for this year. The company also reported advancements in its pharmaceutical drug development programs in epidermolysis bullosa, glaucoma and neurodegenerative diseases.
InMed has announced a conference call and webcast, slated for today at 2 p.m. ET. During the call, the company’s financial and corporate report will be discussed. Those interested can participate by calling (855) 605-1745 in Canada or the United States, and using conference ID 8645175; international participants can call +1 (914) 987-7959, using the same conference ID number. “We have entered a new phase of our corporate evolution, extending our rare cannabinoid focus beyond pharmaceutical drug development to include the growing health and wellness sector where, as an ingredient supplier, we are generating commercial revenues,” said InMed president and CEO Eric Adams in the press release. “We are very pleased with the progress of the integration of BayMedica’s operations and team into our on-going activities at InMed. Within a short timeframe since the acquisition, we have initiated sales of an additional rare cannabinoid, such that our portfolio now includes CBC and CBT. Furthermore, we have accelerated the scale-up manufacturing of additional high demand cannabinoids, including CBDV and THCV, towards commercial launch in the coming months.”
To view the webinar, visit https://ibn.fm/ymOJT
To view the full press release, visit https://ibn.fm/LqyyN
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
